Science News Commentaries

Living in the Era of the Fontan: Failure Should Simply Not be an Option
07/01/2019 | Authors: Jordan D. Awerbach, MD, MPH & Richard A. Krasuski, MD | Pediatric and adult congenital cardiology have undergone dramatic changes over the past 50 years. Nowhere is this better illustrated than in the evolution of treatment for single ventricle anatomy. The Fontan circulation works off the premise that a subpulmonary ventricle is not required to advance blood through the pulmonary vascular bed.
Commentary: Diabetes and Heart Failure, the Double-Edged Sword: Strategies to Co
06/06/2019 | Author: Prakash Deedwania, MD, FAHA | Diabetes mellitus (DM) and Heart Failure (HF) are major public health problems that are increasing throughout the world.
AHA Statement on HIV and Cardiovascular Disease: Clinical Strategies and Future
06/03/2019 | Author: Virginia A. Triant, MD, MPH | Widespread use of antiretroviral therapy (ART) coupled with strategies to expand testing and promote engagement in care has transformed human immunodeficiency virus (HIV) to a chronic disease with a near-normal lifespan.
Evolving Classification and Diagnostic Schemes in Childhood Cardiomyopathies
05/28/2019 | Author: Susan W. Denfield, MD | Since the original phenotypic classification of cardiomyopathies by the World Health Organization (WHO), as dilated (DCM), hypertrophic (HCM) and restrictive (RCM), a number of revised classification schemes have been proposed and published. In the 1980 WHO report cardiomyopathies were defined as heart muscle diseases of unknown cause, while heart muscle disease with a known cause (infective, metabolic/endocrine, storage or infiltrative diseases) were labeled as specific heart muscle disease.
Clinical Cardiovascular Genetics Programs: A Call to Action and a Roadmap
05/23/2019 | Author: Svati H. Shah, MD, MS, MHS, FAHA | I often ask my clinical colleagues, ?How often do you diagnose a patient with a monogenic disease?? Recent attention has been focused on the hope of precision medicine and understanding how genetics contributes to common disease risk and drug response.
The Past, Present, and Future of Cardiac Rehabilitation
05/13/2019 | Nanette Kass Wenger, MD, MACC, MACP, FAHA, MAACVPR | Cardiac rehabilitation is defined as ?the provision of comprehensive long-term services involving medical evaluation; prescriptive exercise; cardiac risk factor modification; and education, counseling, and behavioral interventions.
A Food Systems Perspective for Helping to Achieve AHA Dietary Goals
04/29/2019 | Author: Christopher Gardner, PhD | Food and health are interconnected in many complex ways. Unraveling the complexities involves looking at these connections from multiple perspectives. Nutrients important for health are usually consumed in the context of foods. A characteristic combination of foods can be identified as a food pattern (e.g., Mediterranean).
Exercise-focused Rehabilitation for Cancer Survivors: Creating a CORE Component
04/08/2019 | Author: Kim Dittus, MD, PhD | The publication of the AHA statement, Cardio-Oncology Rehabilitation (CORE) to Manage Cardiovascular Outcomes in Cancer Patients and Survivors, represents a breakthrough for exercise to become standard of care for cancer survivors. Incorporating exercise as part of cancer care has taken a long time.
Insights from the AHA Scientific Statement on Managing Arrhythmias in Patients w
04/04/2019 | Author: Jim Cheung, MD, FACC, FHRS | Left ventricular assist devices (LVADs) have become a mainstay therapy for patients with advanced heart failure by significantly reducing morbidity and mortality. Consequently, the use of LVADs has increased rapidly over recent years.
Myocardial Infarction without Coronary Arterial Obstruction: The Mysterious MINO
03/27/2019 | Author: Joseph S. Alpert, MD | The first time that I heard the term MINOCA, it made me think that perhaps this referred to an ancient civilization in Greece contemporaries of the Minoans on Crete. I imagined the following headline: ?Archeologists unearth the remains of one of the cities of Minoca in northern Greece?. Of course, for cardiologists, MINOCA has nothing to do with ancient Greece.
Are the Lessons Learned From Animal Models of Hypertension Applicable to the Cli
03/14/2019 | Author: Patricia Martinez Quinones, MD and R Clinton Webb, PhD, FAHA | One in three adults in the U.S. has diagnosed high blood pressure. However, taking into consideration the 2017 Hypertension Clinical Guidelines by the AHA and ACC, 130/80 mm Hg rather than 140/90 mm Hg is considered elevated arterial blood pressure.
The Heart-Kidney, Kidney-Heart Connection and Our Improving Understanding of a C
03/11/2019 | Author: Norman E. Lepor, MD FACC and Kevin S Shah, MD | The AHA Scientific Statement on Cardiorenal Syndrome (CRS) provides the most comprehensive and up to date review of this complex set of disease states. There is no more difficult and frustrating disorder that cardiologists and nephrologists are routinely faced with both in the outpatient and inpatient setting then CRS.
The Under-Recognized Burgeoning CV Risks of Water Pipe or Hookah Smoking
03/08/2019 | Author: Debabrata Mukherjee, MD, MS, FAHA | Tobacco use in its various forms remain one of the leading causes of morbidity and mortality worldwide with the World Health Organization estimating that tobacco use accounts for ~ 9% of deaths globally.
Blood Pressure Measurement - a Call to Action to Improve Reliability and Enhance
03/04/2019 | Author: Alberto Avolio, PhD | In addressing the global burden of raised blood pressure, the recent Lancet Commission on Hypertension aimed to raise awareness of the intertwined array of factors that contribute to determining the lifecourse strategy for reduction of cardiovascular risk.
Vascular Toxicity in Cardio-Oncology: The Intersection of Cardiac & Cancer Care
02/21/2019 | Author: Eric H Yang, MD, FACC, FASE and Mirela Tuzovic, MD | Much of the research focus of cardio-oncology has gravitated towards chemoradiation therapies and their association with cardiomyopathy, with well-known culprits such as anthracycline and targeted therapies such as anti-HER2 agents (trastuzumab). However, as Campia and colleagues have demonstrated in their essential AHA Scientific Statement, there are other vasculotoxic effects in both traditional and newer cancer treatments that have been relatively underappreciated.